Allergan (AGN) Structural Monetization Will Take Time, Guggenheim Cuts PT To $190

March 11, 2019 9:19 AM EDT Send to a Friend
Guggenheim analyst, Seamus Fernandez, reiterated his Buy rating on shares of Allergen (NYSE: AGN) and cut his price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login